Immunotherapy-Chemo cocktail shows promise for tough hodgkin lymphoma

NCT ID NCT03618550

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 6 times

Summary

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard GVD chemotherapy can improve outcomes for people with Hodgkin lymphoma that has returned or not responded to initial treatment. About 257 participants will receive up to 4 cycles of the combination before a stem cell transplant. The study is currently recruiting and will measure how many patients achieve a complete response and how long they remain cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (an immunotherapy drug) plus GVD chemotherapy (gemcitabine, vinorelbine, liposomal doxorubicin)
What this could lead to: If successful, this combination could offer a more effective way to shrink Hodgkin lymphoma before a stem cell transplant, potentially improving long-term control of the disease.
What could go wrong: This is a mid-stage trial, so results are not yet proven. The combination may cause significant side effects, and not all patients will respond. Long-term benefits are still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope Cancer Center (Data Collection Only)
NOT_YET_RECRUITING

Duarte, California, 91010, United States
Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States
Stanford University Medical Center
NOT_YET_RECRUITING

Stanford, California, 94305-5408, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.